MA41730A1 - Utilisation de dérivé de benzimidazole pour l'acidité nocturne - Google Patents

Utilisation de dérivé de benzimidazole pour l'acidité nocturne

Info

Publication number
MA41730A1
MA41730A1 MA41730A MA41730A MA41730A1 MA 41730 A1 MA41730 A1 MA 41730A1 MA 41730 A MA41730 A MA 41730A MA 41730 A MA41730 A MA 41730A MA 41730 A1 MA41730 A1 MA 41730A1
Authority
MA
Morocco
Prior art keywords
acidity
benzimidazole derivative
night
present application
derivative compound
Prior art date
Application number
MA41730A
Other languages
English (en)
Other versions
MA41730B1 (fr
Inventor
Ha Jin Lee
Bong Tae Kim
Hyun Kim
Ji Yeon Nam
Jie Eun Park
Geun Seog Song
Shin Young Ryu
Shinichi Koizumi
Nobuyuki Takahashi
Masaomi Tajimi
Original Assignee
Cj Healthcare Corp
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57504150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41730(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cj Healthcare Corp, Raqualia Pharma Inc filed Critical Cj Healthcare Corp
Publication of MA41730A1 publication Critical patent/MA41730A1/fr
Publication of MA41730B1 publication Critical patent/MA41730B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente demande concerne des utilisations d'un composé dérivé de benzimidazole pour remédier à et traiter l'acidité nocturne (nab). Le composé dérivé de benzimidazole selon la présente application permet de prévenir ou de traiter plus efficacement des troubles liés à l'acidité gastrique en améliorant et en traitant efficacement les symptômes d'acidité nocturne.
MA41730A 2015-06-08 2016-06-08 Utilisation de dérivé de benzimidazole pour l'acidité nocturne MA41730B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562172680P 2015-06-08 2015-06-08
PCT/KR2016/006072 WO2016200148A1 (fr) 2015-06-08 2016-06-08 Utilisation de dérivé de benzimidazole pour l'acidité nocturne

Publications (2)

Publication Number Publication Date
MA41730A1 true MA41730A1 (fr) 2018-08-31
MA41730B1 MA41730B1 (fr) 2019-03-29

Family

ID=57504150

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41730A MA41730B1 (fr) 2015-06-08 2016-06-08 Utilisation de dérivé de benzimidazole pour l'acidité nocturne

Country Status (26)

Country Link
US (2) US10512635B2 (fr)
EP (1) EP3305291B1 (fr)
JP (1) JP6792269B2 (fr)
KR (3) KR20160144927A (fr)
CN (2) CN108012527A (fr)
CL (1) CL2017003133A1 (fr)
CY (1) CY1124590T1 (fr)
DK (1) DK3305291T3 (fr)
ES (1) ES2890481T3 (fr)
HK (1) HK1252562A1 (fr)
HR (1) HRP20211046T1 (fr)
HU (1) HUE056322T2 (fr)
IL (1) IL256127B (fr)
LT (1) LT3305291T (fr)
MA (1) MA41730B1 (fr)
MX (1) MX2017015926A (fr)
MY (1) MY197209A (fr)
PH (1) PH12017502221A1 (fr)
PL (1) PL3305291T3 (fr)
PT (1) PT3305291T (fr)
RS (1) RS62074B1 (fr)
RU (1) RU2672248C1 (fr)
SG (1) SG11201710006PA (fr)
SI (1) SI3305291T1 (fr)
TN (1) TN2017000510A1 (fr)
WO (1) WO2016200148A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101960357B1 (ko) 2016-12-26 2019-03-20 씨제이헬스케어 주식회사 벤즈이미다졸 유도체를 포함하는 신규한 제제
KR102262743B1 (ko) * 2017-07-07 2021-06-09 에이치케이이노엔 주식회사 주사용 조성물
JOP20190201A1 (ar) * 2018-08-29 2020-02-29 Hk Inno N Corp تركيبة لاستئصال الملوية البوابية
AU2020225520A1 (en) * 2019-02-18 2021-10-14 Hk Inno.N Corporation Pharmaceutical composition comprising benzimidazole derivative compound
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
US10991185B1 (en) 2020-07-20 2021-04-27 Abbott Laboratories Digital pass verification systems and methods
WO2022086238A1 (fr) * 2020-10-23 2022-04-28 Hk Inno.N Corporation Comprimé à désintégration orale comprenant un composé dérivé de benzimidazole et procédé de préparation associé
KR102648315B1 (ko) * 2021-12-08 2024-03-15 (주) 팜젠사이언스 벤즈이미다졸 유도체 화합물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR043063A1 (es) * 2002-12-13 2005-07-13 Altana Pharma Ag Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas
CA2536902A1 (fr) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Formulations inhibitrices de pompe a proton, et procedes d'elaboration et d'utilisation correspondantes
ATE442140T1 (de) 2005-06-14 2009-09-15 Raqualia Pharma Inc Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten
CN102321077A (zh) * 2005-12-19 2012-01-18 拉夸里亚创药株式会社 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途
EP2068841B1 (fr) 2006-10-05 2018-09-26 Santarus, Inc. Nouvelles formulations pour une libération immédiate d'inhibiteurs de pompe à protons et procédés d'utilisation de ces formulations
WO2008151927A2 (fr) 2007-06-15 2008-12-18 Nycomed Gmbh Dérivés de benzimidazole à substitution 6-n pharmaceutiquement actifs
CA2671369C (fr) 2008-03-10 2011-05-10 Takeda Pharmaceutical Company Limited Cristal de compose de benzimidazole
CN102470126A (zh) 2009-07-09 2012-05-23 拉夸里亚创药株式会社 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂
CN102140099A (zh) 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 新的吡啶衍生物
RU2537140C1 (ru) * 2013-09-17 2014-12-27 Леонид Федосеевич Ляпустин Способ антихеликобактерной терапии желудка и двенадцатиперстной кишки

Also Published As

Publication number Publication date
CN118557572A (zh) 2024-08-30
MX2017015926A (es) 2018-07-06
US10512635B2 (en) 2019-12-24
US11033532B2 (en) 2021-06-15
RS62074B1 (sr) 2021-07-30
KR20200002739A (ko) 2020-01-08
KR20160144927A (ko) 2016-12-19
EP3305291A4 (fr) 2019-01-23
US20200069652A1 (en) 2020-03-05
US20180338954A1 (en) 2018-11-29
WO2016200148A1 (fr) 2016-12-15
CL2017003133A1 (es) 2018-04-13
PL3305291T3 (pl) 2021-11-02
SG11201710006PA (en) 2018-01-30
KR20180036931A (ko) 2018-04-10
ES2890481T3 (es) 2022-01-20
PH12017502221A1 (en) 2018-06-04
KR102061052B1 (ko) 2019-12-31
JP2018516951A (ja) 2018-06-28
DK3305291T3 (da) 2021-06-28
PT3305291T (pt) 2021-07-05
SI3305291T1 (sl) 2021-08-31
CN108012527A (zh) 2018-05-08
HUE056322T2 (hu) 2022-02-28
CY1124590T1 (el) 2022-07-22
EP3305291A1 (fr) 2018-04-11
IL256127A (en) 2018-02-28
MA41730B1 (fr) 2019-03-29
HK1252562A1 (zh) 2019-05-31
HRP20211046T1 (hr) 2021-10-01
LT3305291T (lt) 2021-08-25
IL256127B (en) 2021-04-29
MY197209A (en) 2023-06-01
EP3305291B1 (fr) 2021-05-19
TN2017000510A1 (en) 2019-04-12
JP6792269B2 (ja) 2020-11-25
RU2672248C1 (ru) 2018-11-13

Similar Documents

Publication Publication Date Title
MA41730A1 (fr) Utilisation de dérivé de benzimidazole pour l'acidité nocturne
MX2022001778A (es) Metodos para tratar esquizofrenia.
MA43518B1 (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
ZA201701299B (en) Glycosidase inhibitors
MX2018010192A (es) Inhibidores de glucosidasa.
EA202090749A1 (ru) Способы совместной терапии для иммуномодуляции
MX2018010191A (es) Inhibidores de glucosidasa.
EA202090510A1 (ru) Способ лечения бокового амиотрофического склероза придопидином
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
BR112015020466A2 (pt) inibidores de cdc7
EA201490875A1 (ru) Производное аминоалкилзамещенного n-тиенилбензамида
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
TR201905233T4 (tr) Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi.
MX2019010085A (es) Inhibidores de la glicosidasa de sulfoximina.
TN2016000040A1 (fr) Inhibiteurs de porc2 et procedes pour leur utilisation
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA49373B1 (fr) Compositions comprenant des souches bactériennes
MA46459A (fr) Méthode de traitement de lésions rénales aiguës
MX2020012497A (es) Moduladores de la expresion de apol1.
MX2019002149A (es) Metodo para el tratamiento de prurito y/o comezon.
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1